Drug Database
AR

aripiprazole (Abilify Maintena / Lu AF41155 / aripiprazole ERIS)

✓ Approved

Otsuka Holdings Co., Ltd. · DRD2 · 小分子

什么是 aripiprazole?

aripiprazole 是一种小分子,由Otsuka Holdings Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Abilify Maintena, Lu AF41155, aripiprazole ERIS
公司Otsuka Holdings Co., Ltd.
药物类别小分子
分子靶点DRD2, HTR1A, HTR2A
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

aripiprazole 作用于 3 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
HTR1A5-hydroxytryptamine receptor 1A (PFMCD, 5-HT1A)
HTR2A5-hydroxytryptamine receptor 2A (5-HT2A, HTR2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

aripiprazole 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersSchizophrenia✓ Approved
Psychiatric disordersBipolar disorder✓ Approved

相关研究文献

PubMedEuropean respiratory review : an official journal of the European Respiratory Society2026-08-06

Large animal models of right heart failure due to pulmonary hypertension: a bridge to translational success.

Prins Sally E SE, Blake Madelyn J MJ, Helke Kristi L KL, Di Salvo Thomas T et al.

Right heart failure drives morbidity and mortality in pulmonary arterial hypertension (PAH). At present, there are no chronic pharmaceutical interventions that directly augment right heart function in humans despite many promising results in rodent studies. The lack of translational success may be due to the relative scarcity of studies examining large animal models of right heart failure. However, in recent years, a rapid expansion of large animal investigations worldwide is generating new important physiological and mechanistic data. Large animal models provide more human-relevant biology, which can be paired with physiological assessments and multi-omic profiling to expand our knowledge of right heart failure. Here, we highlight findings obtained from pigs, sheep, cows and dogs, and define some potential limitations of each large animal model. In addition, we outline important questions that could be addressed in future research. Although imperfect, large animals will likely serve important roles in the development of right heart-directed therapies ranging from mechanical interventions to pharmaceutical approaches as they move up the translational pipeline. Hopefully, the field will continue these critical lines of research to promote the discovery of novel therapeutics for our patients who are in desperate need of new options.

PMID 42556847
阅读全文 →
PubMedPharmaceutical research2026-08-06

Continuous Distillation for Drug Substance Manufacturing.

Penzer Kimberly E KE, Gregory Daniel G DG, Turnage Justin T JT, Thieken Colin D CD et al.

Continuous distillation is widely used in the commodity and petrochemical industry to purify fine chemicals on massive industrial scales; however, this key separation strategy is largely unused within the pharmaceutical industry. This article investigates the development of a pilot-scale continuous distillation system for in-line removal of an excess amine reactant (i.e., tert-butylamine) when incorporated within an advanced manufacturing technology (AMT) for continuous drug substance production. Initial design parameters were simulated in ASPEN + to assess potential process solvents, setpoint parameters, and azeotrope formation. Complementary analytical characterization was performed with high performance liquid chromatography (HPLC) and gas chromatography - flame ionization detection (GC-FID). Early continuous distillation prototypes and key engineering design decisions are highlighted. The final engineered system is comprised of a + 3-foot distillation column fitted with an Allihn condenser, a 250 mL three-necked round bottom flask, and an automated system for reflux ratio (RD) control. The column is readily integrated within an advanced manufacturing system to continuously remove amine reagent during continuous manufacturing of albuterol sulfate at a 3.0 mL/min process basis, corresponding to a theoretical throughput of approximately 1,800 doses per hour based on the demonstrated process flowrate, reaction stoichiometry, and operating conditions. The application of continuous distillation offers a unique strategy for impurity removal during advanced pharmaceutical manufacturing and can be scaled to meet target throughputs. Here we provide general criteria necessary for successful implementation of similar continuous in-line distillation systems.

PMID 42560570
阅读全文 →
PubMedRSC advances2026-08-06

Enhanced tetracycline removal from complex real wastewater using a sustainable hog plum-ZnO-Ag2O composite.

Egbedina Abisola O AO, Akinseye Morenike O MO, Bayonle Oladoja A OA, Olu-Owolabi Bamidele I BI et al.

The increasing occurrence of pharmaceutical contaminants such as tetracycline (TC) in aquatic environments poses significant environmental and public health concerns due to their persistence and contribution to antibiotic resistance. In this study, a ZnO/Ag2O-functionalized hog plum (Spondias mombin) composite (MHGP) was synthesized and evaluated for TC removal from aqueous systems. To the best of our knowledge, this represents the first report on the simultaneous ZnO and Ag2O nanoparticle modification of Spondias mombin biomass for antibiotic adsorption and its application in a real wastewater matrix. The successful incorporation of the ZnO and Ag2O nanoparticles onto the hog plum biomass (HGP) was confirmed using multiple physicochemical characterization techniques. Batch adsorption studies revealed that optimum TC removal occurred at pH 2, with an adsorbent dosage of 50 mg achieving maximum TC sequestration from a 25 mg L-1 solution within 4 h. The maximum adsorption capacity (Q max) in ultrapure water was 1.96 mg g-1. Isotherm studies showed that the Brouers-Sotolongo model best described the adsorption in ultrapure water, whereas the Sips isotherms provided a superior fit for real wastewater, indicating heterogeneous adsorption in the presence of competing ions. Kinetic modelling showed that the adsorption followed the pseudo-second-order, suggesting that adsorption may be governed by interactions involving surface functional groups and metal active sites. Despite the chemical complexity of the real wastewater matrix, the MHGP composite maintained a TC removal efficiency of 55%. Overall, these results demonstrate the potential of MHGP as a practical and sustainable adsorbent for pharmaceutical wastewater remediation.

PMID 42559476
阅读全文 →
PubMedToxicology and applied pharmacology2026-08-06

Integrated metabolomic and behavioral profiling reveals neurotoxicity signatures in zebrafish larvae exposed to pharmaceutical compounds.

Rezvanov Pavel M PM, Moskaleva Natalia E NE, Appolonova Elizaveta G EG, Varzieva Valeria G VG et al.

Early detection of neurotoxicity remains a challenge, as functional disturbances often precede overt morphological abnormalities. Zebrafish (Danio rerio) larvae provide a suitable in vivo model for integration of behavioral and biochemical endpoints. In this study, we applied a combined metabolomic and behavioral approach to identify biomarkers of neurotoxicity following exposure to pharmaceutical compounds with diverse mechanisms of action. Locomotor activity was evaluated in zebrafish larvae exposed to selected compounds at sublethal concentrations using a light-dark transition assay. In parallel, targeted metabolomic analysis was performed to quantify metabolites associated with neurotransmitter pathways. Behavioral profiling highlighted distinct pharmacological signatures across drug classes: antipsychotics led to pronounced hypolocomotion and coordination impairment, antidepressants produced moderate and phase-specific activity changes, whereas stimulants promoted increased locomotor activity. Metabolomic analysis demonstrated that the most informative changes were associated with serotonergic, catecholaminergic, and γ-aminobutyric acid (GABA)-related pathways. While pathway-specific alterations reflected pharmacological neuroactivity, coordinated perturbations across multiple neurotransmitter-related pathways were observed for selected compounds, including amitriptyline and ethanol. These changes were accompanied by behavioral alterations consistent with a neurotoxicity-like phenotype. Reduced locomotor activity alone was not a sufficient marker of neurotoxicity as pharmacologically distinct compounds provided similar locomotor effects. Instead, the integration of multidimensional behavioral endpoints with metabolomic data allowed discrimination between pathway-specific neuroactivity and broader neurotoxicity-like effects. Overall, combined metabolomic and behavioral profiling in zebrafish larvae provides a sensitive and mechanistically informative approach for early neurotoxicity assessment. The identified alterations in neurotransmitter-related pathways represent candidate biomarkers associated with neurotoxicity-like responses and support the application of integrated omics-based strategies in toxicological screening.

PMID 42556651
阅读全文 →
PubMedFrontiers in medicine2026-08-06

Reconceiving orphan drug market exclusivity as a conditional public-law entitlement: a sustainable regulatory governance model with comparative lessons for China.

Quan Guiyu G, Zhou Yi Y, Liu Yi Y, Wu Yinan Y et al.

Rare disease patients, who collectively number over 400 million worldwide, remain systematically underserved within existing universal health coverage frameworks. Orphan drug market exclusivity is a widely adopted regulatory incentive designed to stimulate pharmaceutical innovation for rare diseases. Recent regulatory reforms in China, the United States, and the European Union have introduced conditional mechanisms, signaling a shift from static proprietary protection toward a conditional regulatory governance model. Japan, while not undertaking legislative reform in 2026, offers a distinct reference point through its re-examination system. To date, no study has systematically integrated these latest legislative reforms into a comparative regulatory analysis or examined how the institutional design of orphan drug exclusivity can be calibrated to balance innovation incentives with equitable patient access. This study employs an integrated multi-method approach combining comparative legal analysis, doctrinal interpretation, evidence-based policy evaluation, and case analysis. A structured analytical framework is constructed around four key regulatory dimensions-eligibility criteria, exclusivity duration, scope of protection, and exception mechanisms. Using this framework, the study compares the orphan drug exclusivity regimes of the United States, the European Union, and Japan, and assesses the institutional risks embedded in China's newly enacted legislation. This article proposes a novel theoretical model that reconceptualizes orphan drug market exclusivity as a conditional public-law entitlement whose legitimacy is premised on the continuing fulfillment of public health objectives. Applying this framework, the study identifies four core structural deficiencies in China's current regime and, drawing on mature comparative practices, develops targeted institutional design proposals for each regulatory dimension. Reconceiving orphan drug market exclusivity as a conditional public-law entitlement, rather than as an intellectual property right, offers a sustainable governance pathway for reconciling innovation incentives with the equity and financial protection goals of universal health coverage. Embedding conditional constraints into pharmaceutical exclusivity rules ensures that regulatory incentives serve long-term public health objectives and carries implications for addressing market failures and access challenges in other areas of global public health.

PMID 42558582
阅读全文 →
PubMedSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026-08-06

Therapeutic potential of phytochemical compounds in cardiovascular disease: a comprehensive review.

Alatawi Kahdr K

Cardiovascular diseases (CVDs) continue to be the world's leading cause of death and a major global healthcare burden. Concerns about side effects and long-term therapy restrictions have raised interest in supplementary therapeutic approaches, even if traditional pharmaceutical and surgical procedures are still crucial to the management of CVD. Evidence from published experimental, clinical, and mechanistic investigations that were indexed in PubMed, Scopus, Web of Science, and Google Scholar between 2014 and 2025 is compiled in this review. Through their antioxidant, anti-inflammatory, lipid-lowering, antihypertensive, and endothelial-protective properties, plant-derived phytochemicals such as flavonoids, carotenoids, polyphenols, glucosinolates, and sulfur-containing compounds have considerable cardioprotective potential. Vascular function, oxidative stress, platelet aggregation, insulin sensitivity, and lipid metabolism have all benefited by compounds like quercetin, catechins, curcumin, resveratrol, and lycopene. However, its therapeutic translation is still constrained by issues with bioavailability, dosage uniformity, and clinical validation. Although more extensive clinical research is needed to determine their long-term efficacy and safety, the evidence now available indicates that phytochemicals may be beneficial supplements to traditional cardiovascular treatments.

PMID 42560465
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多aripiprazole